Norway· NO-ID_38AFB50F-FCEA-4ABB-AE77-4D2054838722

Ozempic

A semaglutide product containing semaglutide, registered in Norway by Novo Nordisk A/S (2). The same ATC class is registered in 14 of our 19 countries.

ATC A10BJ06

Checked against FEST (Norway) on

Informational only — not a medical device.

SOURCE REGISTER · NOFEST (Norway)normalisedOzempicATCA10BJ06REGISTER NO.NO-ID_38AFB50F-FCEA-4…PACKS LISTED3CHECKEDSeptember 25, 2026

Where it is registered

Semaglutide is registered in 14 of 19 countries.

Countries holding a registration under ATC A10BJ06 (semaglutide), each read from that country’s own register.

  • This record: Norway, from FEST (Norway)
  • 9 of them publish a price we can compare per daily dose

Semaglutide · ATC A10BJ06

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of semaglutide costs, country by country.

Normalised to the WHO defined daily dose (10.5 mg), the median price runs from $11.85 in Italy to $430.99 in Switzerland — a ×36 gap.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Semaglutide · price per daily dose (10.5 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$430.99
  • IT Italy$11.85
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

FEST (Norway)
Active substance
Semaglutide
Manufacturer
Novo Nordisk A/S (2)
Country
Norway (NO)
ATC code
A10BJ06
ATC class
Semaglutide
Defined daily dose
10.5 mg, O
Reimbursed
Not published by this register
Source register
FEST (Norway)
Last checked
September 25, 2026

Packs & prices · 3

1 priced
  • no_merkevare_id
    ID_38AFB50F-FCEA-4ABB-AE77-4D2054838722
  • no_varenummer
    077926
    3
    NOK 2339.3
  • gtin
    5712249133092

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

301 interactions on record for semaglutide.

Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Semaglutide · interactions on record

301 records

  • 3 severe
  • 258 moderate
  • 40 minor

Most severe, free to view

  • GatifloxacinJ01MA16severe
  • SucralfateA02BX02moderate
  • ThiethylperazinA04AB03moderate
  • TriflupromazinA04AD06moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Semaglutide in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All semaglutide products

Authorised across Europe · EMA

The same active substance is authorised in 1 EEA country. Names it is sold under:

  • Iceland · Kayshild, Ozempic

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/e7acbc4a-6451-4be7-b59f-61552f1e7ee3
GET /v1/drugs/e7acbc4a-6451-4be7-b59f-61552f1e7ee3?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Injeksjonsvæske, oppløsning i ferdigfylt penn",
  "source": "fest",
  "status": "A",
  "atc_name": "Semaglutid",
  "merkevare_id": "ID_38AFB50F-FCEA-4ABB-AE77-4D2054838722",
  "name_form_strength": "Ozempic inj, oppl 2 mg/0,74 ml",
  "prescription_group": "C"
}

See everything about semaglutide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.